BioCentury
ARTICLE | Finance

Taking notice

How biotech can maintain momentum in 2Q17

April 7, 2017 11:20 PM UTC

Political overhang during the first quarter kept generalists on the sidelines but provided a buying opportunity for life sciences specialists that led the sector to outperform. With “repeal and replace” in the rearview for now and other sectors cooling off, generalists are beginning to nibble at offerings in the mid-cap space where they think there may be takeouts.

“That outperformance has been pretty good,” Guggenheim Securities’ Susanne Mulligan told BioCentury. “That has caused the generalists to start paying attention again.” ...